Bayer Healthcare LLC

Cara Therapeutics, Inc.

Otsuka Pharmaceutical Company, Limited

Bayer Intellectual Property Gmbh

Jason S Newcom

Barton W Phillips

Steven R Magnuson

Stephen J O'Connor

Kyle E Parcella

Zheng Liu

Zhonghua Zhang

Julie A Dixon

Zhenqiu Hong

Brent Chandler

Gary Gustafson

Harold C E Kluender

Kristen M Allegue

Geraldine C Harriman

Kazumi Kondo

Masaki Suzuki

Akira Takahashi

Shin Miyamura

Uday R Khire

Takeshi Kuroda

Muneaki Kurimura

Amy M Elder

Satoshi Shimizu

Yamin Wang

Martin Michels

Kevin J Hodgetts

Haruka Takahashi

Tae Fukushima

Furahi Achebe

Lei Wang

Indranath Ghosh

Krishna Reddy Valluru

Abhishek Dogra

Julie Dixon

Chengzhi Zhang

Qian Zhao

Gaetan H Ladouceur

Mario Lobell

Robert Zhiyong Luo

Chetan Padmakar Darne

Janet L Ralbovsky

R Paul Beckett

Carla M Gauss

Tindy Li

Zhen Liu

Kanwar Sidhu

Tandy Li

Harold Kluender

Stephen J O'connor

Kristen Allegue

Amy Elder

Methods of treating disorders using compounds that modulate striatal-enriched tyrosine phosphatase (STEP), such as those of formula (III), and composition thereof are described herein. Exemplary disorders include schizophrenia and cognitive deficit. 

Therapeutic compounds and related methods of use

Compounds, pharmaceutical compositions containing the compounds, and methods of using the compounds to treat a disorder, e.g., schizophrenia and cognitive deficit, in a subject are described herein. The compounds disclosed herein include quinoline and quinazoline-containing compounds that modulate striatal-enriched tyrosine phosphatase (STEP) activity.

The present invention provides substituted imidazoheterocycles having the general structure of formula I: wherein Y is chosen from &#x2014;O&#x2014;, &#x2014;OCRR&#x2014;, &#x2014;CRRO&#x2014;, &#x2014;CRR&#x2014;, &#x2014;(CRR)&#x2014;, &#x2014;NR&#x2014;, &#x2014;CRRNR&#x2014; and &#x2014;NRCRR&#x2014;. Also provided are pharmaceutically acceptable salts, acid salts, hydrates, solvates and stereoisomers of the compounds of formula I. The compounds are useful as modulators of cannabinoid receptors and for the prophylaxis and treatment of cannabinoid receptor-associated diseases and conditions, such as pain, inflammation and pruritis.

Substituted imidazoheterocycle derivatives

This invention relates to novel pyrrozolotriazine compounds, pharmaceutical compositions containing such compounds and the use of those compounds and compositions for the prevention and/or treatment of hyper-proliferative disorders and diseases associated with angiogenesis.

Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis

This invention relates to compounds of Formula (I), wherein the variables are as disclosed in the specification, to pharmaceutical compositions containing them, to methods of making the compounds and pharmaceutical compositions, and to methods of using the compounds and pharmaceutical compositions for treating or preventing disorders, in particular cancer.

Tetrahydropyridothienopyrimidine compounds and methods of use thereof

This invention relates to novel pyrrozolotriazine compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients.

The present invention provides benzo-fused heterocyclic compounds having the structure of formula I, as well as prodrugs, stereoisomers, racemates, salts, hydrates, solvates, acid salt hydrates and isomorphic crystalline forms thereof.  The compounds directly or indirectly modulate the activity of one or more cannabinoid receptors and can be incorporated into pharmaceutical preparations that are useful for the prevention and treatment of a variety of diseases and conditions, including pain, inflammation and pruritis.

Benzo-fused heterocycles

The invention provides compounds having the structure of formula I, and prodrugs, stereoisomers, racemates, salts, hydrates, solvates, acid salt hydrates and isomorphic crystalline forms thereof, wherein A, Y and the groups R, R, Rand Rare defined in the specification. These compounds can be administered in pharmaceutical formulations to modulate cannabinoid receptor activity for the prevention and treatment of a variety of diseases and conditions, including pain, inflammation and pruritis.

Substituted pyridoxazines

Growing community of inventors

Norfolk, MA, United States of America

Jason S Newcom